Share on StockTwits

Analysts at JMP Securities lowered their price target on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from $25.00 to $19.00 in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. JMP Securities’ price target suggests a potential upside of 56.90% from the stock’s previous close.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 12.11 on Friday. Keryx Biopharmaceuticals has a one year low of $6.61 and a one year high of $17.46. The stock has a 50-day moving average of $14.77 and a 200-day moving average of $14.06. The company’s market cap is $1.101 billion. Keryx Biopharmaceuticals also saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 19,885,216 shares, an increase of 12.4% from the April 15th total of 17,690,828 shares. Based on an average daily volume of 2,067,905 shares, the short-interest ratio is currently 9.6 days. Approximately 22.7% of the company’s shares are short sold.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.07. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.91 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was up 42.9% on a year-over-year basis. Analysts expect that Keryx Biopharmaceuticals will post $-0.56 EPS for the current fiscal year.

A number of other firms have also recently commented on KERX. Analysts at Ladenburg Thalmann raised their price target on shares of Keryx Biopharmaceuticals from $24.00 to $30.00 in a research note on Friday, April 4th. They now have a “buy” rating on the stock. Separately, analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Wednesday, April 2nd. Finally, analysts at Mizuho raised their price target on shares of Keryx Biopharmaceuticals from $25.00 to $34.00 in a research note on Wednesday, April 2nd. They now have a “buy” rating on the stock. Seven analysts have rated the stock with a buy rating, Keryx Biopharmaceuticals currently has an average rating of “Buy” and a consensus price target of $25.29.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.